Revised SPC: Zometa (zoledronate) Solution for Infusion -

Revised SPC: Zometa (zoledronate) Solution for Infusion
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers | Musculo-skeletal disorders
Summary
The SPC has been updated to include advice about the potential for this medicine to cause osteonecrosis of the external auditory canal and that this should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.
UKMi comment
The MHRA has provided guidance on the association between bisphosphonates and the development of osteonecrosis of the external auditory canal.
Related links: MHRA Drug Safety update